# Leo Cancer Care Closes Oversubscribed $65M Series D to Scale Upright Cancer Care Platform

> financing · REPORTED · 2026-07-08

Leo Cancer Care closed a $65 million oversubscribed Series D round led by Yu Galaxy, with new investor Eventide Asset Management, to commercialize its integrated upright radiotherapy platform. The financing followed a historic June 2026 milestone at Stanford Medicine, where its Marie platform was used to deliver the world's first compact upright proton therapy treatment.

About Leo Cancer Care: Leo Cancer Care is a medical technology company that develops upright imaging and radiotherapy systems, including the Marie compact proton therapy platform, designed to treat cancer patients in a seated upright position rather than lying flat, enabling much smaller treatment rooms.

- Company: Leo Cancer Care
- Sector: oncology
- Primary source: https://www.businesswire.com/news/home/20260708655051/en/Leo-Cancer-Care-Raises-$65M-Series-D-to-Scale-Its-Integrated-Upright-Cancer-Care-Platform

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.